A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
- PMID: 25897676
- PMCID: PMC4430716
- DOI: 10.1038/bjc.2015.126
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
Abstract
Background: The MEK inhibitor, selumetinib, suppresses soft-tissue sarcoma (STS) cell proliferation in vitro. Mammalian target of rapamycin inhibitors possess modest activity against STS; however, resistance develops via MAPK pathway feedback activation. The combination of selumetinib and temsirolimus synergistically inhibits STS cell line growth. Therefore, a randomized phase II trial of selumetinib vs selumetinib plus temsirolimus was conducted.
Methods: Seventy-one adults with advanced STS who received ⩽ 2 prior chemotherapeutics were randomized to selumetinib 75 mg p.o. bid and allowed to crossover upon progression, or to selumetinib 50 mg p.o. bid plus temsirolimus 20 mg i.v. weekly, with primary endpoint of progression-free survival (PFS).
Results: There was no difference in PFS between the two arms for the overall cohort (median 1.9 vs 2.1 months); an improved median PFS was observed in the combination arm (N = 11) over single agent (N = 10) in the prespecified leiomyosarcoma stratum (median 3.7 vs 1.8 months; P = 0.01). Four-month PFS rate was 50% (95% confidence interval 0.19-0.81) with the combination vs 0% with selumetinib alone in the leiomyosarcoma cohort. Most common grade 3/4 adverse events with the combination were mucositis (29%), lymphopenia (26%), neutropenia and anaemia (20% each).
Conclusions: While single-agent selumetinib has no significant activity in STS, the combination may be active for leiomyosarcomas.
Figures
Similar articles
-
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.Lancet Oncol. 2013 Jul;14(8):733-40. doi: 10.1016/S1470-2045(13)70237-7. Epub 2013 Jun 2. Lancet Oncol. 2013. PMID: 23735514 Clinical Trial.
-
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.Invest New Drugs. 2017 Oct;35(5):576-588. doi: 10.1007/s10637-017-0459-7. Epub 2017 Apr 19. Invest New Drugs. 2017. PMID: 28424891 Free PMC article. Clinical Trial.
-
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.Lancet Oncol. 2013 Apr;14(4):371-82. doi: 10.1016/S1470-2045(13)70049-4. Epub 2013 Mar 8. Lancet Oncol. 2013. PMID: 23477833 Free PMC article. Clinical Trial.
-
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470-2045(14)70063-4. Epub 2014 Mar 5. Lancet Oncol. 2014. PMID: 24618336 Clinical Trial.
-
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.Lancet Oncol. 2013 Jan;14(1):38-47. doi: 10.1016/S1470-2045(12)70489-8. Epub 2012 Nov 28. Lancet Oncol. 2013. PMID: 23200175 Clinical Trial.
Cited by
-
Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature.Support Care Cancer. 2024 Aug 23;32(9):610. doi: 10.1007/s00520-024-08810-x. Support Care Cancer. 2024. PMID: 39174797 Review.
-
Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.J Neurooncol. 2024 May;167(3):515-522. doi: 10.1007/s11060-024-04617-2. Epub 2024 Mar 5. J Neurooncol. 2024. PMID: 38443692
-
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma.Front Oncol. 2022 Nov 10;12:1006959. doi: 10.3389/fonc.2022.1006959. eCollection 2022. Front Oncol. 2022. PMID: 36439412 Free PMC article. Review.
-
Understanding the Polyamine and mTOR Pathway Interaction in Breast Cancer Cell Growth.Med Sci (Basel). 2022 Sep 10;10(3):51. doi: 10.3390/medsci10030051. Med Sci (Basel). 2022. PMID: 36135836 Free PMC article.
-
Selumetinib: a selective MEK1 inhibitor for solid tumor treatment.Clin Exp Med. 2023 Jun;23(2):229-244. doi: 10.1007/s10238-021-00783-z. Epub 2022 Feb 16. Clin Exp Med. 2023. PMID: 35171389 Review.
References
-
- Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Investig. 2008;118 (9:3065–3074. - PMC - PubMed
-
- Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J clin oncol. 2012;30 (1:78–84. - PubMed
-
- Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of CT and PET in patients with metastatic GIST treated at a single institution with imatinib mesylate: proposal of new CT response criteria. J Clin Oncol. 2007;25:1753–1759. - PubMed
-
- Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. - PubMed
-
- Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, Socci ND, Behrendt N, Ma L, Maki RG, Pandolfi PP, Cordon-Cardo C. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007;13 (6:748–753. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical